# FOURLIGHT-1 (NCT06105632)

> A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06105632
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Pfizer
- Conditions: Advanced or Metastatic Breast Cancer
- Interventions: PF-07220060 CDK4 inhibitor; Fulvestrant; Everolimus; Exemestane
- Enrollment: 333
- Primary outcome: Progression-Free Survival (PFS) progression, as determined by investigator per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 11

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=fourlight-1-nct06105632

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT06105632", "email": "<work email>"}; the inbox owner confirms by the emailed link.